Abstract Body

Background

DTG resistance is increasingly reported among treatment-experienced people with HIV in low- and middle-income countries. Because most viremia on DTG reflects adherence lapses rather than resistance, guidelines restrict testing to prolonged viraemia, often delaying detection of resistance. We evaluated a laboratory-initiated reflex strategy using plasma DTG exposure to guide resistance testing in routine care.

Methods

We conducted a prospective implementation study on adults with viraemia (≥400 copies/mL) in Johannesburg, South Africa. Plasma DTG exposure was measured on viral load samples using a semi-quantitative enzyme immunoassay, and resistance testing was performed on the same specimen if DTG was detected. Retrospective sequencing of samples with undetectable DTG was used to assess the negative predictive value of this reflex approach for excluding DTG resistance.

Results

We analysed 400 samples from 288 individuals with viremia. Plasma DTG was detectable in 108/288 (38%) individuals in whom DTG resistance was identified in 13/103 (14%). All had prior exposure to non-DTG ART. In individuals with undetectable plasma DTG, the negative predictive value for absence of DTG resistance was 98% (134/137). Detectable DTG and the presence of nucleos(t)ide or non-nucleoside reverse transcriptase mutations were associated with DTG resistance. Of the 68 individuals with repeated viremia (≥2 VL≥400 copies/mL), 43% (30/70) consistently had undetectable plasma DTG-levels and no evidence of DTG resistance. DTG resistance prevalence was similar among individuals with consistently detectable DTG (3/12, 25%) and those with variable DTG exposure over time (5/26, 19%). Cost modelling demonstrated a 22% reduction in laboratory monitoring costs using the reflex strategy compared with current national guidelines.

Conclusions

Laboratory-initiated reflex plasma DTG exposure testing provides an objective, scalable and cost-efficient strategy to direct resistance testing towards individuals at the highest risk of DTG resistance. By distinguishing adherence-related viremia from true drug failure, this approach enables timely individualized treatment decisions while conserving limited resources. Reflex DTG exposure testing has the potential to strengthen HIV treatment monitoring algorithms, reduce emergence of resistance and improve outcomes in programmatic settings. Based on these findings, plasma DTG testing will be incorporated into South African routine clinical care guidelines to triage resistance testing.